Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 4, 2013, Pages 514-519

  Tomkova H ^a   Pospiskova M ^a   Zabojnikova M ^a   Kohoutek, M ^a   Serclova M ^a   Gharibyar, M ^a   Sternbersky J ^a  

^a Krajska Nemocnice T Bati as   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; IRINOTECAN; PANITUMUMAB; PHYTOMENADIONE;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; CREAM; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FEMALE; FOLLICULITIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; MALE; MORNING DOSAGE; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; RECTUM CARCINOMA; SIDE EFFECT; TOPICAL TREATMENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; FOLLICULITIS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; VITAMIN K 1;

EID: 84875369304     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04324.x     Document Type: Article

References (20)

1. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side-effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007; 56: 317-326.
2. Li T, Perez-Soler R,. Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol 2009; 4: 107-119.
3. DeWitt CA, Siroy AE, Stone SP,. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007; 56: 500-505.
4. Mascia F, Mariani V, Girolomoni G, et al. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163: 303-312.
5. Pastore S, Mascia F, Mariani V, Girolomoni G,. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 2008; 128: 1365-1374.
6. Eilers RE Jr, Gandhi M, Patel JD, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010; 102: 47-53.
7. Gerber PA, Kukova G, Buhren BA, Homey B,. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology 2011; 222: 144-147.
8. Perez-Soler R, Ling Y, Zou Y, Deitcher SR,. Local rescue of skin toxicities secondary to kinase inhibitor (KI) therapy with topical menadione. Ann Oncol 2008; 19: v164.
9. Ocvirk J, Rebersek M,. Management cutaneous side effects of cetuximab therapy with K1 vitamin crème. Radiol Oncol 2008; 42: 215-224.
10. Common Terminology Criteria for Adverse Events v4.03 (CTCAE) http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-v4.03-2010-06-14-QuickReference-5x7.pdf (last accessed on 7 July, 2011).
11. Shearer MJ, Newman P,. Metabolism and cell biology of vitamin K. Thromb Haemost 2008; 100: 530-547.
12. Li J, Lin JC, Wang H, et al. Novel role of vitamin K in preventing oxidative injury to developing oligodendrocytes and neurons. J Neurosci 2003; 23: 5816-5826.
13. Vitamin K in Wikipedia http://en.wikipedia.org/wiki/Vitamin-k (last accessed on 2 May, 2011).
14. Klaus V, Hartmann T, Gambini J, et al. 1,4-Naphthoquinones as inducers of oxidative damage and stress signaling in HaCaT human keratinocytes. Arch Biochem Biophys 2010; 496: 93-100.
15. Perez-Soler R, Zou Y, Li T, et al. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. J Clin Oncol 2006; 24: 3036.
16. Perez-Soler R, Zou Y, Li T, Ling Y,. Steroids and immunosuppressive agents potentiate the cytotoxicity of th EGFR inhibitor erlotinib (E) in human skin keratinocytes whereas Vit K3 exerts a protective effect: implications for the management of the skin rash. J Clin Oncol 2007; 25: 9124.
17. Tomková H, Kohoutek M, Zábojníková M, et al. Cetuximab-induced cutaneous toxicity. J Eur Acad Dermatol Venereol 2010; 24: 692-696.
18. Su X, Lacouture ME, Jia Y, Wu S,. Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 2009; 77: 124-133.
19. Tejpar S, Peeters M, Humblet Y, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. J Clin Oncol 2007; 25: 4037.
20. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 1351-1357.